These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35312319)

  • 1. Principles of Kinase Allosteric Inhibition and Pocket Validation.
    Pan Y; Mader MM
    J Med Chem; 2022 Apr; 65(7):5288-5299. PubMed ID: 35312319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
    Carofiglio F; Trisciuzzi D; Gambacorta N; Leonetti F; Stefanachi A; Nicolotti O
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32937901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.
    Nussinov R; Zhang M; Maloney R; Liu Y; Tsai CJ; Jang H
    J Mol Biol; 2022 Sep; 434(17):167569. PubMed ID: 35378118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.
    Lu S; He X; Ni D; Zhang J
    J Med Chem; 2019 Jul; 62(14):6405-6421. PubMed ID: 30817889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
    Kakarala KK; Jamil K
    J Biomol Struct Dyn; 2022 Sep; 40(15):6889-6909. PubMed ID: 33682622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
    Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
    J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
    Gray NS; Fabbro D
    Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
    Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
    J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
    Hantschel O; Grebien F; Superti-Furga G
    Cancer Res; 2012 Oct; 72(19):4890-5. PubMed ID: 23002203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors.
    Lee BJ; Shah NP
    Leukemia; 2017 May; 31(5):1096-1107. PubMed ID: 27890928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.
    Panicker RC; Chattopadhaya S; Coyne AG; Srinivasan R
    Adv Exp Med Biol; 2019; 1163():253-278. PubMed ID: 31707707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric inhibitors of Bcr-Abl: towards novel myristate-pocket binders.
    Radi M; Schenone S; Botta M
    Curr Pharm Biotechnol; 2013; 14(5):477-87. PubMed ID: 22429131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
    Mian AA; Metodieva A; Badura S; Khateb M; Ruimi N; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
    BMC Cancer; 2012 Sep; 12():411. PubMed ID: 22985168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.
    Dong J; Lu W; Pan X; Su P; Shi Y; Wang J; Zhang J
    Bioorg Med Chem; 2014 Dec; 22(24):6876-84. PubMed ID: 25464886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
    Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
    Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding the diversity of allosteric bcr-abl inhibitors.
    Deng X; Okram B; Ding Q; Zhang J; Choi Y; Adrián FJ; Wojciechowski A; Zhang G; Che J; Bursulaya B; Cowan-Jacob SW; Rummel G; Sim T; Gray NS
    J Med Chem; 2010 Oct; 53(19):6934-46. PubMed ID: 20828158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric inhibition of BCR-ABL.
    Hassan AQ; Sharma SV; Warmuth M
    Cell Cycle; 2010 Sep; 9(18):3710-4. PubMed ID: 20930519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.
    Mian AA; Oancea C; Zhao Z; Ottmann OG; Ruthardt M
    Leukemia; 2009 Dec; 23(12):2242-7. PubMed ID: 19798092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations.
    Mingione VR; Foda ZH; Paung Y; Philipose H; Rangwala AM; Shan Y; Seeliger MA
    J Mol Biol; 2022 Sep; 434(17):167628. PubMed ID: 35595169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.